European Congress of Pathology (ECP)

Emilia Andersson is the oncology lead at Roche Medical and Governmental Affairs team in the EMEA-LATAM region. She is a certified pathologist in surgical pathology and cytopathology from Karolinska University Hospital. Her thesis on biomarkers in tumor immunology led her to Roche Pharma where she worked with exploration of the tumor microenvironment and development of new biomarker analysis in clinical studies including multiplex analyses and digital algorithms. Before rejoining Roche she was the Medical Director for Pathology at Unilabs in Sweden, directing a large group of about 50 pathologists and 200 staff, implementing digital pathology for primary diagnosis on a large scale. She was also leader of the Unilabs international pathology expert team. Emilia is the former president of the Swedish board of pathologists and was heavily involved in implementing national guidelines for digital pathology and pre-analysis. She is still practicing clinical pathology as a consultant.

Dr Magali Lacroix-Triki, MD, PhD, President of the French Division of the International Academy of Pathology (AIP-DF), is an expert breast pathologist, with a strong involvement in translational research. She is the referent pathologist of several multicentric national and international breast clinical trials in the Unicancer frame. She is also the referent pathologist of the Unicancer Personalized Medicine Committee, and was the coordinator of the French GEFPICS group, comprising breast pathologists all over France and Belgium, until November 2021. She joined Gustave Roussy Cancer Campus in December 2015 (Pathology Department and Pr Fabrice ANDRE INSERM U981 Research Unit).

Nadim is currently a lecturer at Nova School of Business and Economics where he teaches strategy and innovation for the Masters, MBA and Executive Education programs. He is also a member of the Strategic Board of the Research Institute for Medicines at the University of Lisbon, and Coordinator of the Health Care Policy Think Tank at SEDES where he has coordinated and authored several studies on healthcare policy and management. He additionally works as a consultant and speaker in the field of organizational agility and high-performance organizations, with a special emphasis on healthcare delivery and performance.

Dr. Federico Rojo (MD, PhD) is a Senior Physician in Pathology at Fundación Jiménez Díaz (FJD) University Hospital in Madrid since 2007, where he is also the leader of the Molecular Pathology Laboratory and the Head of the Pathology Department. He is the Head of the Research Breast Cancer Group, Coordinator of the Cancer Research Area and Scientific Director of the Biobank at the Biomedical Research Institute of the same institution, IIS-FJD. Since 2010, he is also the president of the pathologist group at Spanish Breast Cancer Research Group, GEICAM, and member of GEICAM´s Steering Committee. In 2017-19, Dr Rojo developed the role of Secretary of the Spanish Society of Pathology, SEAP.  He completed his training as a medical resident in Pathology between 1995 and 1998 in Hospital Vall d’Hebron, Barcelona, where he also conducted his PhD in Molecular Biology in Cancer for 7 years in the oncology group, led by Dr. Baselga. He enjoyed an international stay during this period at the MD Anderson Cancer Center in Texas.

Dr. Umberto Malapelle is the Chief of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples and the Scientific Secretary of the International Society of Liquid Biopsy. His main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor. Moreover, he has developed skills in tailoring Next Generation Assays for a number of different applications with a special focus on the simultaneously detection of clinical relevant alterations (i.e. EGFR mutations, ALK translocation, PD–L1 expression) in the routine setting including handling of different sample types, such as tissues and/or liquid biopsy specimens.

Prof. dr. Léon van Kempen is a clinical scientist in molecular pathology and is currently the director of the laboratory for molecular diagnostics at the Antwerp University Hospital, Belgium. He obtained his PhD in molecular pathology from the University of Nijmegen (The Netherlands) and subsequently specialized in molecular diagnostics. He was the Chief Officer of Operations at the Molecular Pathology Center at the Jewish General Hospital (McGill University, Montréal, Canada) and subsequently member of staff at the department of Pathology of the University Medial Center Groningen (UMCG, The Netherlands).  As an expert in molecular diagnostics, was a member of the UMCG MTB and is currently a member of the Belgian national MTB (NCT05058937).

His current research activities can be found here .

Graduated in Pharmaceutical Sciences from the Faculty of Pharmacy of the University of Porto (1995), with a masters degree in Applied Human Genetics from the Faculty of Sciences of the University of Porto (1998), and a PhD degree in Biomedical Sciences from the School of Medicine and Biomedical Sciences (ICBAS) at the University of Porto (2019). Specialized in Human Genetics dedicated to the molecular diagnosis of hereditary predisposition to cancer and acquired genetic alterations relevant for diagnosis or prognosis, or predictive of response to targeted therapies, in the Department of Laboratory Genetics of the Portuguese Institute of Oncology of Porto. Author/co-author of 68 scientific publications in international indexed journals.

Dearbhaile is an Irish trained Consultant Medical Oncologist with speciality interest in lung cancer and gynecological malignancies but also treats a variety of other cancers. She has both a PhD in translational oncology and MA in Medical Ethics and Law. She has extensive experience in both surgical and medical oncology with numerous publications, presentations, grants and awards. She is a recipient of the Irish Cancer Society Clinician Research Leadership Award 2020 that ring fences protected academic time for her to pursue her translational research interests. 

Dearbhaile currently works as a Consultant Medical Oncologist at Cork University Hospital and Kerry University Hospital, and she is a Senior Lecturer in Cancer Research with University College Cork.

Pathologist and Ph.D., current Medical Affairs Director for Breast Cancer in Roche Diagnostics Solutions. Member of the European Society of Pathology and the Spanish Society of Pathology. Special emphasis on bringing Companion Diagnostic into clinical practice and pathologists training. Joined Roche in 2016.